Quarterly ResultMay 5, 2026, 07:33 AM
Nuvectis Pharma Q1 Net Loss $6.1M; NXP900 Phase 1b Enrollment Continues
AI Summary
Nuvectis Pharma reported its first quarter 2026 financial results, with a net loss of $6.1 million, an increase from $5.3 million in the prior year. Cash and cash equivalents were $25.1 million as of March 31, 2026. The company continues to advance its NXP900 Phase 1b clinical program, actively enrolling patients in the US, and expects a preliminary data readout in the summer. Preclinical data supporting NXP900's use in non-small cell lung cancer was also presented at the AACR conference.
Key Highlights
- Net loss for Q1 2026 was $6.1 million, up from $5.3 million in Q1 2025.
- Cash and cash equivalents were $25.1 million as of March 31, 2026.
- Research and development expenses increased to $4.1 million in Q1 2026.
- General and administrative expenses rose to $2.2 million in Q1 2026.
- NXP900 Phase 1b clinical program continues patient enrollment in the US.
- Preliminary data from NXP900 Phase 1b study expected in summer 2026.
- Preclinical data for NXP900 in NSCLC presented at AACR conference.